Literature DB >> 33923088

Decorating sdAbs with Chelators: Effect of Conjugation on Biodistribution and Functionality.

Henri Baudhuin1, Janik Puttemans1, Heleen Hanssens1, Philippe Vanwolleghem1, Sophie Hernot1, Geert Raes2,3, Catarina Xavier1, Tony Lahoutte1,4, Pieterjan Debie1.   

Abstract

Single domain antibodies (sdAbs) have proven to be valuable probes for molecular imaging. In order to produce such probes, one stn class="Species">rategy is the functionalization of the reactive amine side chain of lysines with a chelator, resulting in a mixture of compounds with a different degree of conjugation. In this study, we implemented anion exchange chromatography (AEX) to separate the different compounds or fractions that were further characterized and evaluated to study the impact of the conjugation degree on pharmacokinetic properties and functionality. Anti-HER2 and anti-MMR sdAbs were functionalized with NOTA or DTPA chelator. Anion exchange chromatography was performed using 0.02 mol/L Tris pH 7.5 as the first solvent and 0.25 M or 0.4 M NaCl (in case of NOTA chelator or DTPA chelator, respectively) as the second solvent applied as a gradient. The fractions were characterized via mass spectrometry (MS), surface plasmon resonance (SPR), and isoelectric focusing gel electrophoresis (IEF), while in vivo studies were performed after radiolabeling with either 68Ga (NOTA) or 111In (DTPA) to assess the impact of the conjugation degree on pharmacokinetics. AEX could successfully be applied to separate fractions of (chelator)n-anti-HER2 and (chelator)n-anti-MMR sdAb constructs. MS confirmed the identity of different peaks obtained in the separation process. SPR measurement suggests a small loss of affinity for (chelator)3-anti-sdAb, while IEF revealed a correlated decrease in isoelectric point (pI) with the number of conjugated chelators. Interestingly, both the reduction in affinity and in pI was stronger with the DTPA chelator than with NOTA for both sdAbs. In vivo data showed no significant differences in organ uptake for any construct, except for (DTPA)n-anti-MMR, which showed a significantly higher liver uptake for (DTPA)1-anti-MMR compared to (DTPA)2-anti-MMR and (DTPA)3-anti-MMR. For all constructs in general, high kidney uptake was observed, due to the typical renal clearance of sdAb-based tracers. The kidney uptake showed significant differences between fractions of a same construct and indicates that a higher conjugation degree improves kidney clearance. AEX allows the separation of sdAbs with a different degree of conjugation and provides the opportunity to further characterize individual fractions. The conjugation of a chelator to sdAbs can alter some properties of the tracers, such as pI; however, the impact on the general biodistribution profile and tumor targeting was minimal.

Entities:  

Keywords:  bioconjugation; ion exchange chromatography; kidney clearance; molecular imaging; radiopharmaceutical; tracer optimization

Year:  2021        PMID: 33923088     DOI: 10.3390/ph14050407

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  49 in total

Review 1.  Effects of charge on antibody tissue distribution and pharmacokinetics.

Authors:  C Andrew Boswell; Devin B Tesar; Kiran Mukhyala; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli
Journal:  Bioconjug Chem       Date:  2010-11-05       Impact factor: 4.774

2.  Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.

Authors:  Karin Knogler; Jürgen Grünberg; Ilse Novak-Hofer; Kurt Zimmermann; P August Schubiger
Journal:  Nucl Med Biol       Date:  2006-10       Impact factor: 2.408

Review 3.  Antibodies for molecular imaging of cancer.

Authors:  Anna M Wu; Tove Olafsen
Journal:  Cancer J       Date:  2008 May-Jun       Impact factor: 3.360

4.  Molecular imaging using Nanobodies: a case study.

Authors:  Nick Devoogdt; Catarina Xavier; Sophie Hernot; Ilse Vaneycken; Matthias D'Huyvetter; Jens De Vos; Sam Massa; Patrick De Baetselier; Vicky Caveliers; Tony Lahoutte
Journal:  Methods Mol Biol       Date:  2012

5.  Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging.

Authors:  Sam Massa; Catarina Xavier; Jens De Vos; Vicky Caveliers; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Bioconjug Chem       Date:  2014-05-09       Impact factor: 4.774

6.  Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.

Authors:  Catarina Xavier; Ilse Vaneycken; Matthias D'huyvetter; Johannes Heemskerk; Marleen Keyaerts; Cécile Vincke; Nick Devoogdt; Serge Muyldermans; Tony Lahoutte; Vicky Caveliers
Journal:  J Nucl Med       Date:  2013-03-13       Impact factor: 10.057

7.  Electrophoretic method for the quantitative determination of a benzyl-DTPA ligand in DTPA monoclonal antibody conjugates.

Authors:  D T Pham; F M Kaspersen; E S Bos
Journal:  Bioconjug Chem       Date:  1995 May-Jun       Impact factor: 4.774

8.  Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells.

Authors:  S A Linehan; L Martínez-Pomares; P D Stahl; S Gordon
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

9.  Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Authors:  Jens Sörensen; Irina Velikyan; Dan Sandberg; Anders Wennborg; Joachim Feldwisch; Vladimir Tolmachev; Anna Orlova; Mattias Sandström; Mark Lubberink; Helena Olofsson; Jörgen Carlsson; Henrik Lindman
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

10.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Authors:  G Gebhart; L E Lamberts; Z Wimana; C Garcia; P Emonts; L Ameye; S Stroobants; M Huizing; P Aftimos; J Tol; W J G Oyen; D J Vugts; O S Hoekstra; C P Schröder; C W Menke-van der Houven van Oordt; T Guiot; A H Brouwers; A Awada; E G E de Vries; P Flamen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.